What Verita Neuro does

Verita Neuro is a privately held, Singapore-incorporated healthcare services company founded in 2015 that delivers neurorestorative treatments for spinal cord injuries, brain injuries, stroke, and other neurological conditions. It operates as a direct-to-consumer provider, reaching patients globally through social media content, live Q&A webinars, and organic search, then funneling them through free consultations to multi-week (3-8 week) inpatient programs at company-owned and partnered treatment centers in Bangkok, Guadalajara, Calgary, Dubai, and (opening 2026) Lviv. Treatment revenue is generated through professional service fees for each program; pricing is quote-based and not publicly disclosed.

The clinical platform combines three technology domains: neuromodulation (epidural stimulation, brain stimulation, vagus nerve stimulation), regenerative medicine (mesenchymal and amniotic fluid stem cells delivered via intra-spinal, intrathecal, and intravenous routes), and robotic rehabilitation (the FDA-approved ReWalk Personal Exoskeleton, which Verita distributes exclusively in Mexico, Thailand, and UAE under a 2025 partnership with Lifeward). Proprietary technology includes the LamiSpine procedure, a laminectomy combined with direct intra-spinal stem cell injection, and a specialized stem cell processing pipeline including unique clonal amniotic fluid stem cell culture methods. The company claims a 3:1 patient-to-staff ratio and is documented as the first provider globally to offer epidural stimulation for neurological restoration.

The business model is a fee-for-service specialty clinic with a self-pay international patient base; 99 patients from 30 countries were treated in 2025, alongside 44 epidural stimulation surgeries, 71 stem cell treatments, and 11 LamiSpine surgeries. The company is founder/management-owned with no disclosed institutional funding rounds, no public revenue disclosure, and 11-50 employees. Customers are individual patients rather than enterprise accounts, with the only enterprise relationship being the Lifeward distribution alliance.

Name

Verita Neuro

Legal name

Verita Neuro Pte. Ltd.

Website

https://veritaneuro.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Verita Neuro is a Singapore-based private healthcare provider operating international treatment centers that deliver neurorestorative treatments combining neuromodulation, stem cell therapy, and robotic exoskeleton rehabilitation for spinal cord injury, brain injury, stroke, and other neurological conditions, serving self-pay patients globally.

Ownership category

akta.pro rank

Product category

Neurological Rehabilitation Services

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)

akta.pro primary industry

Neurorehabilitation Centers (HLAFAFAH)

akta.pro secondary industries

Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Neurological Rehabilitation Therapy In-Home (e.g., Stroke, Parkinson’s) (HSABADAE), Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

Keywords

• Neurorestorative treatments
• Spinal cord injury
• Neuromodulation therapy
• Regenerative medicine
• Brain stimulation

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Neurorestorative Treatment Programs: Verita Neuro generates revenue through direct healthcare service fees for its treatment programs including Epidural Stimulation, Stem Cell treatments, LamiSpine, Brain Stimulation, and ReWalk Exoskeleton rehabilitation. Programs typically run 3-8 weeks at company treatment centers in Thailand, Mexico, UAE, Canada, and Ukraine. Pricing is not publicly disclosed and handled through individual consultation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels10 records

Core offering

Verita Neuro delivers neurorestorative medical treatment programs combining neuromodulation (epidural stimulation, brain stimulation, vagus nerve stimulation), regenerative medicine (stem cell therapies), and robotic rehabilitation (ReWalk exoskeleton) for patients with spinal cord injuries, brain injuries, stroke, and other neurological conditions. Treatments are delivered at company-owned and partnered international treatment centers across Thailand, Mexico, Canada, UAE, and Ukraine through intensive 3-8 week programs.

Product overview

Verita Neuro is a pioneering global leader in neurorestorative treatments, offering a comprehensive portfolio of advanced neuromodulation and regenerative medicine solutions for neurological conditions and spinal cord injuries. The company provides six core treatments: Epidural Stimulation (implanted spinal cord stimulation for voluntary movement), Brain Stimulation (neuromodulation for stroke/brain injury), LamiSpine (surgical decompression combined with intra-spinal stem cell delivery), Stem Cell Treatment (mesenchymal and amniotic fluid stem cells via multiple delivery methods), Vagus Nerve Stimulation (minimally invasive neuromodulation), and the ReWalk Personal Exoskeleton (FDA-approved wearable robotic device for walking and stair climbing). These treatments are delivered through international treatment centers in Thailand, Mexico, Canada, UAE, and Ukraine (opening 2026), with flagship facilities in Bangkok and Guadalajara.

Differentiator

Problem solved

Functional benefit

Products and services

• Epidural Stimulation Implantation of an electronic device onto the spinal cord that activates motor neurons through precise electrical stimulation to help patients regain voluntary movement in lower or upper limbs. Used for spinal cord injury patients with injury levels C5 to T11, combined with daily physical therapy over a 35-day program.
• LamiSpine Proprietary surgical procedure combining laminectomy decompression with direct intra-spinal stem cell injection. Delivers mesenchymal and amniotic fluid stem cells directly into the injured spinal cord tissue through targeted injection, performed over a three-week stay including intensive neurorehabilitation.
• Brain Stimulation Neuromodulation treatment for Stroke and Brain Injury recovery using targeted electrical stimulation to encourage movement and speech recovery.
• Stem Cell Treatment Regenerative treatment using mesenchymal stem cells from umbilical cord Wharton's jelly and amniotic fluid stem cells to restore function and reduce inflammation in neurological and autoimmune conditions. Administered via intrathecal, intravenous, and/or intramedullary injection.
• Vagus Nerve Stimulation Minimally invasive neuromodulation treatment for Stroke and Traumatic Brain Injury that stimulates the vagus nerve to promote recovery of motor and cognitive function.
• ReWalk Personal Exoskeleton FDA-approved robotic exoskeleton for paraplegic spinal cord injury patients that enables walking and stair climbing in everyday life. Controlled via a watch and cane, integrated into Verita Neuro's multi-modal neurorehabilitation programs combining surgical neural stimulation, stem cell therapy, and intensive rehabilitation.

Quantifiable outcome

• 99 patients treated from 30 countries in 2025
• +3 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Unbroken National Rehabilitation Center (Ukraine)coreStrategic or Co-development Partner · 7 July 2026Landmark partnership to establish Verita Neuro's first European treatment center in Lviv, Ukraine. The center will provide neurorestorative care for spinal cord injury patients using pioneering microchip technology. The partnership was formalized with an agreement signing ceremony and represents Verita Neuro's expansion into Europe.
• Fakeeh University Hospital (Dubai, UAE)coreStrategic or Co-development Partner · 1 January 2026Partnership to open Middle East treatment center at Fakeeh University Hospital in Dubai, UAE. The center provides neurological and spinal cord injury treatments to patients in the Middle East region, extending Verita Neuro's geographic footprint.
• Lifeward LtdcoreChannel Partner/ Reseller/ Distributor · 17 December 2025Verita Neuro became exclusive distributor of Lifeward's ReWalk Personal Exoskeleton in Mexico, Thailand, and UAE. The agreement integrates the FDA-approved exoskeleton into Verita Neuro's in-patient neurorehabilitation programs that include surgical neural stimulation, stem cell therapy, and intensive rehabilitation. This supports Lifeward's strategy to expand global access to wearable robotic exoskeletons beyond its direct sales operations in the US and Germany.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Regional players

• Medipost (Cartistem/Pneumostem): South Korea-based commercial stem cell therapy company with approved products in orthopedic and neurological indications. Comparable as a regional stem cell therapy operator with clinical infrastructure and regulatory approvals Verita Neuro lacks in major Western markets.
• Phoenix Healthcare Group: Operates specialty medical and rehabilitation centers across Asia and Europe. Comparable as a multi-site, internationally operated neurorehabilitation and medical tourism provider.

Direct peers

• InVivo Therapeutics: Clinical-stage biomaterials and cellular therapy company focused on spinal cord injury treatment. Comparable as a directly competing SCI therapeutic developer using novel neuro-restorative approaches.
• Restorative Therapies: Manufacturer of functional electrical stimulation (FES) therapy cycles, including the RT300 and Xcite, for spinal cord injury and stroke rehabilitation. Comparable as a neurorehabilitation technology provider with overlapping SCI/stroke patient populations.
• Lifeward (formerly ReWalk Robotics): Maker of the ReWalk Personal Exoskeleton, currently Verita Neuro's exclusive distribution partner across Mexico, Thailand, and UAE. Comparable as a neurorestorative technology company focused on spinal cord injury and stroke recovery, with overlapping robotics-based rehabilitation offerings.

Emerging players

• Neuralink: Brain-computer interface developer targeting paralysis and neurological disorders. Comparable as a frontier neurotechnology company pursuing restoration of function in SCI and related conditions.
• BrainStorm Cell Therapeutics: Clinical-stage developer of autologous stem cell therapies (NurOwn) for ALS and other neurodegenerative diseases. Comparable as a stem cell therapy developer targeting motor neuron disease and neuroinflammatory conditions.
• CytoDyn: Clinical-stage biotechnology company developing leronlimab for HIV, oncology, and inflammatory neurological conditions. Comparable as an emerging player in neuroinflammatory and regenerative therapeutics.
• Mesoblast: Commercial-stage regenerative medicine company developing cellular therapies for inflammatory and immune-mediated diseases. Comparable as a stem cell therapeutic developer targeting neurological and autoimmune indications.

Broad incumbents

• Ekso Bionics: Develops and sells robotic exoskeletons (EksoGT, EksoNR) for stroke and spinal cord injury rehabilitation. Comparable as a neurorehabilitation robotics provider serving similar clinical populations across hospitals and rehab centers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/VeritaNeuro
• YouTubeyoutube.com/c/VeritaNeuro
• Facebookfacebook.com/VeritaNeuro
• LinkedInlinkedin.com/company/verita-neuro
• Instagraminstagram.com/veritaneuro
• TikToktiktok.com/@veritaneuro

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verita Neuro